HR-2374 : Still Just a Bill

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Action Timeline

Action DateTypeTextSource
2020-12-24CalendarsPlaced on the Union Calendar, Calendar No. 577.House floor actions
2020-12-24CommitteeReported by the Committee on Judiciary. H. Rept. 116-694.House floor actions
2019-04-30CommitteeOrdered to be Reported by Voice Vote.House committee actions
2019-04-30CommitteeCommittee Consideration and Mark-up Session Held.House committee actions
2019-04-29IntroReferralReferred to the House Committee on the Judiciary.House floor actions
2019-04-29IntroReferralIntroduced in HouseLibrary of Congress

Sponsor :

Hakeem S. Jeffries [D] (NY-8)
See Cosponsors

Policy Area :

Health
Related Subjects
  • Administrative law and regulatory procedures
  • Business ethics
  • Civil actions and liability
  • Competition and antitrust
  • Drug safety, medical device, and laboratory regulation
  • Licensing and registrations
  • Public participation and lobbying
Related Geographic Entities
Related Organizations
  • Federal Trade Commission (FTC)

Related Bills

See Related Bills